SCHEMBL25102016

SCHEMBL25102016

CCN1CCN(CCC2CCN(C(C)C)CC2)CC12CC2

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.33
VCP P55072 1/20 0.32
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25089862 0.95 HRH3 (0.32) HRH3VCPSIGMAR1
SCHEMBL25089857 0.88 HRH3 (0.32) HRH3VCP
SCHEMBL26141959 0.88 HRH3 (0.33) HRH3VCP
SCHEMBL26329778 0.86 HRH3 (0.32) HRH3VCPSIGMAR1
SCHEMBL25101610 0.83 HRH3 (0.32) HRH3VCPSIGMAR1
SCHEMBL24940836 0.77 HRH3 (0.31) HRH3VCP
SCHEMBL24865976 0.77 NCF1 (0.32) SIGMAR1
SCHEMBL24940841 0.76 HRH3 (0.33) HRH3VCPSIGMAR1
SCHEMBL20046477 0.76 VCP (0.44) HRH3VCP
SCHEMBL22301687 0.75 HRH3 (0.40) HRH3VCPSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20230331722-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-10-19 US disclosed
US-20230066136-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230066136-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 HRH3 2014/4885VCP 61/4885SIGMAR1 3159/4885
US-20230331722-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 HRH3 2014/4885VCP 61/4885SIGMAR1 3159/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 HRH3 2014/4885VCP 61/4885SIGMAR1 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.